|
1
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelialmesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moody SE, Perez D, Pan TC, et al: The
transcriptional repressor Snail promotes mammary tumor recurrence.
Cancer Cell. 8:197–209. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shioiri M, Shida T, Koda K, et al: Slug
expression is an independent prognostic parameter for poor survival
in colorectal carcinoma patients. Br J Cancer. 94:1816–1822. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang MH, Chen CL, Chau GY, et al:
Comprehensive analysis of the independent effect of twist and snail
in promoting metastasis of hepatocellular carcinoma. Hepatology.
50:1464–1474. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou YM, Cao L, Li B, et al:
Clinicopathological significance of ZEB1 protein in patients with
hepatocellular carcinoma. Ann Surg Oncol. 19:1700–1706. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Siegel PM and Massagué J: Cytostatic and
apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev
Cancer. 3:807–821. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mima K, Okabe H, Ishimoto T, et al: CD44s
regulates the TGF-β-mediated mesenchymal phenotype and is
associated with poor prognosis in patients with hepatocellular
carcinoma. Cancer Res. 72:3414–3423. 2012.PubMed/NCBI
|
|
9
|
Liver Cancer Study Group of Japan: The
General Rules for the Clinical and Pathological Study of Primary
Liver Cancer. Kanehara, Tokyo: 2009
|
|
10
|
Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y
and Makuuchi M: Staging of hepatocellular carcinoma: assessment of
the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772
patients in Japan. Ann Surg. 245:909–922. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vauthey JN, Lauwers GY, Esnaola NF, et al:
Simplified staging for hepatocellular carcinoma. J Clin Oncol.
20:1527–1536. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Okabe H, Beppu T, Hayashi H, et al:
Hepatic stellate cells accelerate the malignant behavior of
cholangiocarcinoma cells. Ann Surg Oncol. 18:1175–1184. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang MH, Hsu DS, Wang HW, et al: Bmi1 is
essential in Twist1-induced epithelial-mesenchymal transition. Nat
Cell Biol. 12:982–992. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Iwatsuki M, Mimori K, Fukagawa T, et al:
The clinical significance of vimentin-expressing gastric cancer
cells in bone marrow. Ann Surg Oncol. 17:2526–2533. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vora HH, Patel NA, Rajvik KN, et al:
Cytokeratin and vimentin expression in breast cancer. Int J Biol
Markers. 24:38–46. 2009.PubMed/NCBI
|
|
16
|
Padua D, Zhang XH, Wang Q, et al: TGFbeta
primes breast tumors for lung metastasis seeding through
angiopoietin-like 4. Cell. 133:66–77. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yin JJ, Selander K, Chirgwin JM, et al:
TGF-beta signaling blockade inhibits PTHrP secretion by breast
cancer cells and bone metastases development. J Clin Invest.
103:197–206. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bedossa P, Peltier E, Terris B, Franco D
and Poynard T: Transforming growth factor-beta 1 (TGF-beta 1) and
TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human
livers. Hepatology. 21:760–766. 1995.PubMed/NCBI
|
|
19
|
Abou-Shady M, Baer HU, Friess H, et al:
Transforming growth factor betas and their signaling receptors in
human hepatocellular carcinoma. Am J Surg. 177:209–215. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee TK, Man K, Poon RT, et al: Signal
transducers and activators of transcription 5b activation enhances
hepatocellular carcinoma aggressiveness through induction of
epithelial-mesenchymal transition. Cancer Res. 66:9948–9956. 2006.
View Article : Google Scholar
|
|
21
|
Chen L, Chan TH, Yuan YF, et al: CHD1L
promotes hepatocellular carcinoma progression and metastasis in
mice and is associated with these processes in human patients. J
Clin Invest. 120:1178–1191. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chung KY, Cheng IK, Ching AK, Chu JH, Lai
PB and Wong N: Block of proliferation 1 (BOP1) plays an oncogenic
role in hepatocellular carcinoma by promoting
epithelial-to-mesenchymal transition. Hepatology. 54:307–318. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fu J, Chen Y, Cao J, et al: p28GANK
overexpression accelerates hepatocellular carcinoma invasiveness
and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible
factor-1alpha pathways. Hepatology. 53:181–192. 2011. View Article : Google Scholar
|
|
24
|
Kim H, Choi GH, Na DC, et al: Human
hepatocellular carcinomas with “stemness”-related marker
expression: keratin 19 expression and a poor prognosis. Hepatology.
54:1707–1717. 2011.
|
|
25
|
Wang J, Chen L, Li Y and Guan XY:
Overexpression of cathepsin Z contributes to tumor metastasis by
inducing epithelial-mesenchymal transition in hepatocellular
carcinoma. PLoS One. 6:e249672011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yokomizo C, Yamaguchi K, Itoh Y, et al:
High expression of p300 in HCC predicts shortened overall survival
in association with enhanced epithelial mesenchymal transition of
HCC cells. Cancer Lett. 310:140–147. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhu K, Dai Z, Pan Q, et al: Metadherin
promotes hepatocellular carcinoma metastasis through induction of
epithelial-mesenchymal transition. Clin Cancer Res. 17:7294–7302.
2011. View Article : Google Scholar : PubMed/NCBI
|
